---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-027147"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-23T00:09:51.840142+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics elects Dr. Thomas J. Lynch Jr. to Board of Directors

## Summary
- Dr. Lynch appointed as Class I Director with term ending at 2024 annual meeting.
- Received option to purchase 32,000 shares vesting equally over three years.
- Appointed to the Science Committee of the Board.
- Compensation per non-employee director policy; indemnification agreement to be entered.
- No material transactions or arrangements with Dr. Lynch.

## SEC filing metadata
- accession: 0001628280-22-027147
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828022027147/0001628280-22-027147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828022027147/fhtx-20221027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-027147
- JSON: https://secwatch.observer/filing/0001628280-22-027147.json
- Plain text: https://secwatch.observer/filing/0001628280-22-027147.txt

## Key facts
- Executive change
  Thomas J. Lynch Jr., MD was elected as Class I Director at Foghorn Therapeutics Inc..
  - Action: elected
  - Role: Class I Director
  source text: On October 27, 2022, the Board of Directors (the “Board”) of Foghorn Therapeutics Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee, elected Thomas J. Lynch Jr., MD to the Board as a Class I Director with a term to expire at the 2024 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822462/000162828022027147/0001628280-22-027147-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.